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Background: Takayasu arteritis (TA) is an idiopathic large-vessel vasculitis that can result in significant morbidity and
mortality secondary to progressive stenosis and occlusion. Monitoring disease progression is crucial to preventing
relapse, but is often complicated by the lack of clinical symptoms in the setting of active disease. Although acute phase
reactants such as ESR and CRP are generally used as an indicator of inflammation and disease activity, mounting
evidence suggests that these markers cannot reliably distinguish active from inactive TA.
Case presentation: We report a 24-year-old Hispanic female with a 5-year history of TA who presented with stroke-like
symptoms and evidence of left MCA occlusion on imaging, despite a history of decreasing inflammatory markers. CTA
revealed complete occlusion of the left common carotid artery, left subclavian, and left MCA from their origins. It also
revealed a striking compensatory circulation supplying the left anterior circulation as well as the left subclavian as a
response to progressive stenosis.
Conclusion: Monitoring ESR and CRP levels alone may not be a reliable method to evaluate disease progression in
patients with TA, and should be taken in context with both patient’s clinical picture and the imaging. We recommend
that serial imaging be performed regularly in the setting of active disease to monitor progression and allow for
immediate therapy in response to evidence of disease advancement, with a relaxation of the imaging interval once the
disease is presumed inactive.
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Takayasu arteritis (TA) is an idiopathic large vessel vas-
culitis that primarily affects the aorta and its main
branches. Although the prevalence and clinical outcome
of TA varies globally, the annual incidence of TA in the
United States is reportedly 2.6 per million with a 5-year
survival rate as high as 94% [1,2]. The disease predomin-
antly affects women and typically presents during the
second to third decade of life [3]. Signs and symptoms
of TA are diverse and reflect both the stage of the dis-
ease and the affected vasculature. Early stage TA can
present with nonspecific symptoms such as fatigue,
weight loss, and low grade fever, but as the disease pro-
gresses it can manifest as vascular bruits, claudication,
retinopathy, and ischemia due to arterial occlusion [4].* Correspondence: vhedna@mail.ufl.edu
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unless otherwise stated.The evolution of these symptoms is due to progressing
vascular lesions secondary to inflammatory processes [5].
TA is generally monitored closely because relapses are
often unpredictable and dangerous. Inflammatory markers
such as erythrocyte sedimentation rate (ESR) and C - react-
ive protein (CRP) are commonly used to monitor disease
progression during remission due to their noninvasive na-
ture and affordable cost, while the radiation diagnostic
technique CT angiography (CTA) is reserved for patients
presenting with active disease. Despite these monitoring
techniques, assessment of disease activity and progression
in TA remains a challenge [6]. However, relying on the in-
flammatory marker ESR to distinguish active from inactive
TA yields only a 72% sensitivity and a 56% specificity pre-
dictor value [7]. As a result, relying on these markers dur-
ing asymptomatic periods can potentially lead to the false
assumption that the patient is in remission while there is
ongoing active fibrosis and progressive occlusion. In fact,
one study found histologically active disease in 44% ofral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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progression in 61% of patients previously believed to be in
remission [7]. As a result, mounting evidence suggests it
may be necessary to use more invasive imaging to accur-
ately determine active disease.
We present a patient who suffered an ischemic stroke
in spite of improving inflammatory markers suggestive
of disease remission. This patient’s clinical course sup-
ports the hypothesis that inflammatory markers alone
may not be sufficient to track the progression of TA,
and reaffirms the need to monitor disease progression
with more extensive screening. In addition, this patient
demonstrated a remarkable capacity via collaterals to
compensate in the setting of progressive occlusion. In
response to active disease, utilization of vascular reserve
through collateral circulation eventually resulted in
retrograde flow through the vertebral artery to perfuse
tissue distal to severe stenosis of the common carotid ar-
tery (CCA).
Case presentation
A 24 year-old woman with Takayasu’s arteritis (TA) and a
recent history of progressive diffuse headaches presented
to an outside hospital with altered mental status following
loss of consciousness. Five years previously the patient
was diagnosed with anti-myeloperoxidase (MPO) and p-
ANCA vasculitis with an ESR of 57 mm/hr and a CRP of
75 mg/L (Figure 1, initial diagnosis). The patient was pre-
scribed cellcept and a prednisone taper, but was lost to fol-
low up until two years later when she developed hand
numbness, headaches, and postprandial abdominal pain.
CTA revealed 90% stenosis of the superior mesenteric ar-
tery, and ESR and CRP were elevated at 33 mm/hr and













































































Figure 1 ESR and CRP values over timespan of treatment.patient was treated with cellcept and high-dose prednisone
but was again lost to follow up.
At the age of 23 the patient presented to the emer-
gency department with postprandial abdominal pain,
and CTA indicated progression of her disease with lu-
minal narrowing due to intimal thickening of the aortic
arch, descending aorta, and left subclavian artery that
was characteristic of large vessel disease consistent with
Takayasu’s arteritis. Her ESR and CRP were 28 mm/hr
and 7.1 mg/L, respectively, and the following day, her
ESR was 15 mm/hr (Figure 1, 3rd presentation). Imuran
50 mg/d was started with plans to titrate the dose; how-
ever she discontinued her treatment after 3 weeks due
to persistent nausea and vomiting.
Four months later the patient complained of progres-
sive, persistent, diffuse pounding headaches that were as-
sociated with dizziness and blurry vision, and she was
admitted to the hospital for further evaluation. At that
time she was not on any immunosuppressant therapy.
ESR was within normal limits at 19 mm/hr and CRP was
only mildly elevated at 8.9 mg/L (Figure 1, 4th presenta-
tion). But CTA of the head, neck, chest, abdomen, and
pelvis demonstrated further progression of her disease
with circumferential thickening of the aortic arch and sig-
nificant narrowing of the proximal descending thoracic
aorta, along with a severe stenosis of the left common ca-
rotid artery at its origin, 1 centimeter in length (Figure 2A).
There was complete occlusion of the left proximal sub-
clavian artery at its origin from the aortic arch, with flow
in the distal left subclavian artery provided by the left ver-
tebral artery, suggestive of subclavian steal (Figure 2B),
and with reconstitution of flow at the bifurcation of the
vertebral artery suggesting collateral flow was arising from
the posterior circulation. Carotid ultrasound indicated the
left vertebral artery was patent with retrograde flow.
Imuran was stopped and cellcept was restarted with a
60 mg prednisone taper; however, she refused pulse ste-
roids due to concerns weight gain and also refused cytoxan
again. Over the next several weeks the patient continued
to experience worsening headaches unrelieved by over the
counter pain medications. She also became noncompliant
with cellcept.
One month later, the patient presented to an outside
hospital with right sided weakness and speech difficultly.
After CT ruled out hemorrhage, recombinant tissue plas-
minogen activator (t-PA) was administered within the
therapeutic window and the patient was transferred to our
hospital for further work up. On admission, the patient
was limited to following one step commands. Neurologic
exam demonstrated anomia, dysarthria, a right lower facial
droop, and severe weakness on the right upper and lower
extremity. The strength in left upper and lower extremities







Figure 2 CTAs three months before CVA. Oblique lateral MPR view CT angiogram of the neck showing a thrombosed left common carotid
artery (LCCA) with a high-grade stenosis at the origin of the common carotid, 1 cm in length (A). Transverse CTA just above the origin of the
great vessels revealing complete occlusion of the left proximal subclavian artery (LSA) (B), with flow to the distal left subclavian artery provided
by the left vertebral artery, indicative of subclavian steal (C).
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ing of the aortic arch that was consistent with previous
images. There was also complete occlusion of the left
common carotid artery at its origin (Figure 3) and left in-
ternal carotid artery, with collateral flow arising from the
right anterior circulation via the circle of Willis and lepto-
meningeal collaterals. In addition, there is complete occlu-
sion of a short segment of the MCA, just past its
bifurcation (Figure 4A) and evidence of flow through the
anterior and posterior communicating arteries is absent
upon imaging (Figure 4). These findings would explain the
CT perfusion abnormalities of delay in transit time with
decreased cerebral blood flow and cerebral blood volume,
consistent with the left MCA infarct, including the left
basal ganglia (Figure 5).A
Figure 3 CTA of the neck immediately following CVA. Anterior (A) and
thrombosis of the proximal and mid left common carotid artery (arrows).Initially, the patient’s ESR was elevated at 54 mm/hr
(Figure 1, stroke). The patient was started on pulse ste-
roids the day following her stroke. On the fifth day of ad-
mission repeat ESR was 6 mm/hr and CRP was within
normal limits at 3.4 mg/L (Figure 1, Post-CVA). Strength
in the right upper and lower extremity improved while fa-
cial droop and speech deficit persisted. After 8 days the
patient was discharged to an inpatient rehabilitation facil-
ity, where she continued to improve and can now walk
unassisted and perform all of her activities of daily living.
Six months following the patient’s cerebrovascular at-
tack (CVA), the patient’s ESR returned to the normal
range at 10 mm/hr and her CRP value remained elevated
at 19.5 mg/L (Figure 1, 6 months post-CVA). CTA of the
head and neck showed encephalomalacia related to theB






Figure 4 Subtracted 3D CT angiogram following CVA. Oblique view showing high-grade stenosis of left MCA with M2 M3 branches opacified
by retrograde flow through leptomeningeal collaterals (A). Neither posterior communicating artery (A) nor anterior communicating artery (B)
visible upon imaging in oblique and AP views, respectively.
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carotid artery, and a striking complete lack of flow in the
left internal carotid artery (Figure 6).
Discussion
We presented a patient who experienced progressive
vascular lesions due to TA culminating in an ischemic
stroke despite normalizing levels of inflammatory markers.
TA is a large-vessel pan-arteritis affecting predomin-
antly the aorta and its major branches. Its etiology is
unknown, but its pathogenesis is suggestive of an auto-
immune process and is likely multifactorial [5]. The
pathophysiology of this disease can be divided into
early, intermediate and chronic stages [3]. Early in the
disease process, lymphocytes infiltrate the adventitia
through activated vasa-vasorum endothelial cells. The
lymphocytes are stimulated by circulating cytokines to
produce matrix metalloproteinases (MMP), leading to the
destruction of the elastic fibers in the arterial wall. In-
creased adventitial neovascularization and up-regulation
of adhesion molecules results in increased recruitment of
inflammatory cells. In the intermediate stage, there isFigure 5 Brain CT imaging post CVA. Brain CT showing completed infar
and left insular cortex. Cytotoxic edema present (A). CT perfusion shows in
reduced cerebral blood flow (D) in the core left MCA territory.secondary deposition of mucopolysaccharides and fibro-
blasts and smooth muscle cell proliferation, encouraged
by TNF-alpha. Eventually the intima becomes hypertro-
phied due to fibrocellular thickening. The pathological
changes occurring in all layers lead to the narrowing of
the vascular lumen, which result in stenosis and occlusion.
In the chronic phase, inflammatory lesions progress to
scars and the vessels become fibrotic and calcified [8].
When fibrosis is insufficient, as when lesions progress rap-
idly, the arterial wall is thinned and dilation and aneu-
rysms occur. In addition to the primary lesions of TA that
occur in the elastic arteries, affecting both the media and
adventitia through the vasa-vasorum, peripheral branches
of affected arteries are disrupted as well. In these periph-
eral branches, intimal thickening occurs in the absence of
associated changes in the media and adventitia, leading to
occlusion and secondary ischemic lesions to the kidneys,
heart, and brain [9]. The spread of vascular lesions in TA
is thought to develop systemically rather than from adja-
cent vascular beds [5].
Although our patient was managed using cellcept and
prednisone, her noncompliance made it difficult toct in left middle cerebral artery territory affecting the left basal ganglia





Figure 6 Imaging from 6 months following initial acute CVA. Brain CT showing encephalomalacia related to the previous infarct of the left
basal ganglia and left insular cortex (left MCA territory). (A) Transverse slice through neck showing complete occlusion of left common carotid
artery (B). Subtracted 3D CT angiogram showing a complete lack of flow in left internal carotid artery as well as a recanalization of the previous
area of left MCA thrombosis (C).
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corticosteroids, with immunosuppressants and cytotoxic
agents prescribed in treatment-resistant and refractory
cases. Reports indicate that half of all patients who achieve
remission through treatment will eventually relapse, and
one fourth of patients are unable to achieve remission with
either glucocorticoids or glucocorticoids in combination
with cytotoxic agents [7]. Alternative therapies that have
been used with success in refractory cases of TA include
infliximab, tocilizumab, rituximab, tacrolimus, methotrex-
ate, azathioprine, cyclophosphamide, mycophenolate mofe-
til, and leflunomide [10–14]. Given the high probability of
relapse and potential disastrous consequences, it is neces-
sary to frequently and reliably monitor progression.
In every phase of TA management, from the initial
diagnosis to the monitoring of quiescent periods, flares
and remission, clinical examination, biomarker data, and
imaging are all critical components TA evaluation. None
of these assessment techniques can be used in isolation
to sufficiently evaluate disease state [15].
For the clinical assessment of TA, several indexes have
been developed. For TA diagnosis, the 1990 American
College of Rheumatology (ACR) criteria for TA classifica-
tion was developed. This index contains of six criteria: 1)
Age of onset <40 years; 2) Claudication of extremities; 3)
Decreased brachial artery pulse; 4) A systolic blood pres-
sure difference of >10 mm Hg between arms; 5) A bruit of
the subclavian arteries or aorta; and 6) An arteriogram ab-
normality. If three or more of these criteria are met, a TA
diagnosis can be made with a sensitivity of 90.5% and a
specificity of 97.8% [16]. TA disease activity can be
assessed with the National Institutes of Health (NIH) cri-
teria for active disease, with active disease defined as the
new onset or worsening of two of the following four cri-
teria: 1) Systemic features, such as fever and malaise, with
no other cause identified; 2) Elevated erythrocyte sedimen-
tation rate; 3) features of vascular ischemia or inflamma-
tion (claudication, diminished or absent pulses, bruit,vascular pain, asymmetric blood pressure); and 4) Typ-
ical angiographic features [7]. The Disease Extent
Index-Takayasu (DEI-Tak) is an index consisting of 71
items designed for the follow-up of TA based solely on
clinical findings, eliminating the requirement of im-
aging. Though time-consuming to administer, the DEI-
Tak shows good agreement with the NIH criteria [17].
The Indian Takayasu’s Arteritis Score (ITAS) was devel-
oped from the DEI-Tak and modified to optimize inter-
rater reliability and reflection of disease activity. The
ITAS consists of 44 items, 33 of which pertain to the car-
diovascular system, and 7 of which are weighted more
heavily. The ITAS is sensitive to effective medical inter-
ventions, and a high ITAS score denotes poor control of
disease activity [18].
This patient’s case is unique because inflammatory
markers were decreasing over several years despite ac-
tive disease and progressive lesions. Acute-phase reac-
tants such as ESR and CRP are commonly used to
monitor disease progression in TA. Despite their usage,
neither ESR nor CRP can distinguish active from in-
active disease with the necessary clinical accuracy
[19,20]. ESR has a sensitivity and specificity for active
TA of 72% and 56%, while CRP has a sensitivity of
71.4% and specificity up to 100% for active disease
[7,21] (Table 1). However, TA can relapse and active dis-
ease can persist in the absence of elevated CRP and ESR
[21]. Neither ESR nor CRP correlate with MR findings
of vascular edema identified with electrocardiogram-
gated edema-weighted MR [22]. In addition, both ESR
and CRP are suppressed by factors other than disease
remission. ESR can be influenced by extraneous factors
such as medication usage and blood viscosity and CRP ex-
hibits nonspecific elevation in response to tissue inflamma-
tion and infection. Additionally, CRP is produced in the
liver in response to the circulating cytokine IL-6, rather
than at the site of inflammation, which may account for its
low sensitivity [7,21,23]. Relying on these inflammatory
Table 1 Efficacy of serological markers and imaging modalities in the diagnosis of TA
Modality Sensitivity (%) Specificity (%) Citation
ESR 72* 56* Kerr, Hallahan, Giordano, et al., 1994†,‡ [7]
CRP 71.4* 100* Ishihara, Haraguchi, Tezuka, et al., 2012†,§,¶ [21]
FDG-PET 92* 100* Webb, Chambers, AL-Nahhas, et al., 2004†,‡,§ [34]
MRA 100* 100* Yamada, Nakagawa, Himeno, et al., 2000‡ [31]
CTA 95* 100* Yamada, Nakagawa, Himeno, et al., 1998‡ [27]
PTX-3 82.1-89** 87-94.1** Ishihara, Haraguchi, Tezuka, et al., 2012†,§,¶, [21] Dagna, Salvo, Tiraboschi, et al., 2011†,‡,§ [23]
*In diagnosing TA.
**In distinguishing active from inactive disease.
TA diagnosis or disease activity state determined by;
†Clinical assessment.
‡Typical findings on conventional angiography.
§Patients met 1990 American College of Rheumatology criteria for TA diagnosis.
¶MRA.
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vere and even lethal consequences for patients [8,10].
Therefore, ESR and CRP should be viewed in the context
of the patient’s clinical course and imaging.
The unreliability of ESR and CRP has prompted the
search for a more reliable serological marker of disease ac-
tivity. Many biomarker candidates have been identified.
Park et al. examined the serum profiles of inflammatory
cytokines and found that TNF-alpha, IL-6 and IL-18 were
elevated in TA, and of these, IL-18 correlated best with re-
mission [24]. De Souza et al. found that higher homocyst-
eine levels in TA is a risk factor for cardiovascular events
[25]. In evaluating serum ghrelin and leptin levels as po-
tential biomarkers for TA, Yilmaz et al. found that ghrelin
levels were negatively correlated with disease activity and
that the leptin/ghrelin ratio was higher in TA [26]. Regu-
lated and normal T cell-expressed and secreted (RANTES)
levels are increased in active TA and correlate with disease
activity [5]. Dagna et al. found that Pentraxin-3 (PTX-3)
levels are positively correlated with disease state and deter-
mined PTX-3 to be more predictive of TA disease state
than ESR or CRP, with a sensitivity of 89% and specificity
of 87%. An additional benefit of PTX-3 over conventional
markers is that PTX-3 did not show nonspecific eleva-
tion in healthy controls or in response to infection [23].
Though all require further validation, these serological
markers show promise as future biomarkers for TA.
In addition to biomarkers, imaging is indispensable for
the diagnosis and monitoring of TA. Imaging methods
useful for TA include digital subtraction angiography
(DSA), computed tomography angiography (CTA), mag-
netic resonance imaging (MRI), ultrasonography, and
positron emission tomography with radiolabelled glucose
(FDG-PET). Angiography can be used for both screening
and treatment. It has a high sensitivity and specificity for
TA diagnosis, a short study time, is minimally invasive,
and allows for easy comparison of studies performed
throughout disease progression. In comparison to stand-
ard angiography, CTA has a high sensitivity and specificityfor assessing stenotic lesions, 93% and 98%, respectively,
with an overall sensitivity and specificity of 95% and 100%
in diagnosis [27]. CTA allows evaluation of the vessel wall
and lumen in the aorta and large vessels and can provide
information concerning end organ ischemia. However, it is
costly, exposes the patient to higher radiation than other
imaging modalities, and is impractical for frequent moni-
toring [8,28].
MRI is noninvasive, lacks radiation, and can detect
anatomic and pathophysiologic changes such as vascular
lesions, sites of inflammation, and wall thickening [26].
T2 imaging can visualize vessel edema, a sign of inflam-
mation, and a specialized T2 weighted technique, short
tau inversion recovery (STIR), is ideal for imaging soft tis-
sue inflammation [22,29]. MR angiography (MRA) with
gadolinium contrast facilitates visualization of pathological
wall enhancement and has demonstrated a sensitivity and
specificity of up to 100% in diagnosing TA [30,31]. How-
ever, MRI is time consuming, expensive, can be affected
by movement artifact, cannot be performed in patients
with ferromagnetic implants, and may require 3 Tesla
strength in order to visualize smaller vessels [8].
Ultrasonography (US) is non-invasive, cheap, painless,
and avoids ionizing radiation, making it excellent tool for
frequent monitoring of TA. It can be used to identify the
presence of stenosis, estimate blood flow, and assess vessel
anatomy, the lumen, and vessel wall alterations. Addition-
ally, US has a high resolution of approximately 0.1 mm,
providing 10x the resolution of MRI [32,33].
FDG-PET can assess metabolic activity of the vascular
wall, highlighting regions of inflammation. As inflam-
mation begins before morphological changes in the arterial
wall manifest, FDG-PET can facilitate earlier diagnosis.
FDG-PET has shown a sensitivity of 92% and a specifi-
city of 100% in diagnosing TA and is more sensitive
than MRA in detecting vascular involvement in early TA
[34,35]. PET findings of inflammation normalize after
treatment with immunosuppressants, mirroring clinical
improvement, making PET a reliable indicator of disease
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systemic diseases and diagnosing TA [36]. However, it is ex-
pensive, not widely available, exposes the patient to radi-
ation, is limited to vessels greater than 4 mm in diameter,
and cannot be used to examine the vessel wall [28,32].
In our patient, it is possible that complications from her
disease could have been prevented if serial imaging allowed
for treatment to be implemented before manifestations oc-
curred. However, the literature guiding how TA should be
managed and how often imaging should be performed in
these patients is limited, lacking placebo-controlled, ran-
domized controlled trials and consisting primarily of case
series, open studies, and expert opinion [15]. Additionally,
local considerations, such as technique availability and pro-
vider expertise, will also impact which imaging modality is
implemented, further complicating the concept of a univer-
sal imaging algorithm for TA [28]. Three case reports pro-
vide insight on feasible imaging intervals. In the first case,
improvement in vascular lesions on CTA was seen within
6 months of initial presentation with an ischemic stroke
[3]. The second report was an instance of TA causing pul-
monary stenosis and occlusion. Improvement of lesions
was shown on four imaging modalities, gadolinium-
enhanced MRI, two dimensional transesophageal echocar-
diography (TEE), pulmonary angiography, and FDG-PET.
Remarkably, improvements were seen after only 6 weeks
of steroid therapy [37]. In a third report, TA diagnosis was
made with FDG-PET, which showed F-18 FDG uptake in
the aorta, subclavian, and brachiocephalic arteries. Follow-
ing two months of successful immunosuppressant therapy,
with remission of clinical symptoms, the patient was again
imaged with FDG-PET, revealing a dramatic decrease in
F-18 FDG uptake in the affected vessels [38]. Serial im-
aging is important for monitoring TA patients both for re-
mission and relapse, to gauge the effectiveness of current
therapies and to detect subclinical progression of vascular
lesions. We recommend conservative imaging intervals for
both of these periods, with more frequent imaging during
active disease and regular imaging even in the absence of
clinical symptoms during remission.
Another remarkable feature of this case was the labyrin-
thine supply of cerebral blood flow, with collateral and
retrograde flow compensating for severe stenosis and
eventual complete occlusion of several vessels. In our pa-
tient, both her left common carotid artery and left sub-
clavian artery progressed from severe stenosis to complete
occlusion. Despite complete occlusion at its origin, the left
common carotid was patent. CTA imaging revealed the
occipital artery was the predominant collateral supply to
the left anterior circulation, supplying retrograde flow
through the external carotid. Additionally, Transcranial
Doppler revealed stenosis of her left subclavian artery was
compensated by retrograde flow through her left vertebral
artery. It has been reported that the slow progression ofstenosis can allow for the development of collateral circu-
lation, delaying or minimizing symptoms of vascular com-
promise [4]. Our patient’s compensatory circulation was
protective against left hemisphere ischemia and delayed
the onset of neurological symptoms. This case demon-
strates the incredible compensatory capacity of these ves-
sels in the setting of ongoing stenosis.
This patient suffered an ischemic stroke due to the pro-
gressive occlusion of her cerebral arteries secondary to her
TA. In some cases, when the threat from stenosis becomes
severe, endovascular or surgical revascularization proce-
dures may be required. These procedures should be re-
served for the inactive phase of the disease, and for stents,
disease flare ups can cause re-occlusion of both the af-
fected artery and the stent. Balloon angioplasty and stent
graft replacements can be used in the setting of short-
segment arterial stenosis, whereas long-segment stenosis
requires a complete surgical bypass [15]. It is possible that
the current patient could have benefitted from revasculari-
zation procedures, especially around the time of her
fourth presentation, when critical stenosis of several extra-
cranial large vessels was becoming apparent and both her
ESR and CRP were within normal limits.Conclusions
This case suggests that inflammatory markers alone are
not sufficient to monitor disease activity, highlighting the
need for frequent follow up imaging. We recommend that
serial imaging be performed regularly in the setting of ac-
tive disease until patient demonstrates evidence of remis-
sion, with an extended imaging interval in the context of
inactive disease. This case is also serves as a reminder of
the importance of regular visits and compliance in TA
management. This patient had extended periods between
visits, presenting only when symptoms reemerged, and
frequently became noncompliant with medication. It is
likely that her disease course would have been less severe
with more robust patient education, continued communi-
cation with providers, regular follow up, and medication
compliance.
These time intervals provide a means to assess treat-
ment efficacy and allow for immediate intervention in re-
sponse to disease exacerbation. Furthermore, this case
provides a striking example of how collateral and retro-
grade circulation can compensate for the progressive sten-
osis associated with TA.Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
O’Connor et al. BMC Neurology 2014, 14:62 Page 8 of 9
http://www.biomedcentral.com/1471-2377/14/62Abbreviations
ESR: Erythrocyte sedimentation rate; CRP: C-reactive protein; MCA: Middle
cerebral artery; CTA: CT angiogram; MRA: Magnetic resonance angiogram;
CCA: Common carotid artery; CVA: Cerebrovascular attack; MMP: Matrix
metalloproteinase; TNF-alpha: Tumor necrosis factor alpha; PTX: Pentraxin;
TEE: Transeophageal echocardiogram.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Study concept and design: TEO, HEC, VSH. Acquisition of data: TEO, HEC.
Analysis and interpretation of data: TEO, HEC, VSH. Drafting and critical
revision of manuscript: TEO, HEC, VSH. Statistical analysis: TEO, HEC, VSH.
Administrative, technical, and material support: SB, MFW, VSH. Study
supervision: SB, MFW, VSH. All authors read and approved the final
manuscript.
Acknowledgement
Publication of this article was funded in part by the University of Florida
Open-Access Publishing Fund.
Author details
1College of Medicine, University of Florida, Gainesville, FL, USA. 2Department
of Neuroscience, University of Florida, Gainesville, FL, USA. 3Department of
Neurology, University of Florida, Room L3-100, McKnight Brain Institute 1149
Newell Drive, Gainesville, FL 32611, USA. 4Department of Radiology,
University of Florida, Gainesville, FL, USA.
Received: 9 October 2013 Accepted: 21 March 2014
Published: 28 March 2014
References
1. Hall S, Barr W, Lie JT, Stanson AW, Kazmier FJ, Hunder GG: Takayasu
arteritis. A study of 32 North American patients. Medicine (Baltimore) 1985,
64:89–99.
2. Sadurska E, Jawniak R, Majewski M, Czekajska-Chehab E: Takayasu arteritis
as a cause of arterial hypertension. Case report and literature review.
Eur J Pediatr 2012, 171:863–869.
3. Hedna VS, Patel A, Bidari S, Elder M, Hoh BL, Yachnis A, Waters MF:
Takayasu’s Arteritis: is it a reversible disease? Case report and literature
review. Surg Neurol Int 2012, 3:132.
4. Castaner E, Alguersuari A, Andreu M, Gallardo X, Spinu C, Mata JM:
Imaging findings in pulmonary vasculitis. Semin Ultrasound CT MR
2012, 33:567–579.
5. Arnaud L, Haroche J, Mathian A, Gorochov G, Amoura Z: Pathogenesis of
Takayasu’s arteritis: a 2011 update. Autoimmun Rev 2011, 11:61–67.
6. Direskeneli H, Aydin SZ, Merkel PA: Assessment of disease activity and
progression in Takayasu’s arteritis. Clin Exp Rheumatol 2011, 29:S86–S91.
7. Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, Hoffman GS:
Takayasu arteritis. Ann Intern Med 1994, 120:919–929.
8. Bryl M, Guzinski M, Rabczynski M, Waliszewska-Prosol M, Garcarek J, Adamiec R,
Sasiadek M: Imaging difficulties in Takayasu arteritis - case report and review
of the literature. Pol J Radiol 2012, 77:67–71.
9. Hotchi M: Pathological studies on Takayasu arteritis. Heart Vessels Suppl
1992, 7:11–17.
10. Mahlmann A, Pfluecke C, Ouda A, Simonis G, Weiss N, Kappert U:
Combined immunosuppressive therapy including a TNF-alpha blocker
induces remission in a difficult to treat patient with Takayasu arteriitis
and coronary involvement. Vasa 2012, 41:451–457.
11. Bravo Mancheno B, Perin F, Guez Vazquez Del Rey Mdel M, Garcia
Sanchez A, Alcazar Romero PP: Successful tocilizumab treatment in a
child with refractory Takayasu arteritis. Pediatrics 2012,
130:e1720–e1724.
12. Ernst D, Greer M, Stoll M, Meyer-Olson D, Schmidt RE, Witte T: Remission
achieved in refractory advanced takayasu arteritis using rituximab.
Case Report Rheumatol 2012, 2012:406963.
13. Yamazaki H, Nanki T, Harigai M, Miyasaka N: Successful treatment of refractory
Takayasu arteritis with tacrolimus. J Rheumatol 2012, 39:1487–1488.
14. Unizony S, Stone JH, Stone JR: New treatment strategies in large-vessel
vasculitis. Curr Opin Rheumatol 2013, 25:3–9.15. Keser G, Direskeneli H, Aksu K: Management of Takayasu arteritis: a
systematic review. Rheumatology 2013 [Epub ahead of print].
16. Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM,
Fauci AS, Leavitt RY, Lie JT, Lightfoot RW Jr, Masi AT, McShane DJ, Mills JA,
Stevens MB, Wallace SL, Zvaifler NJ: The American College of
Rheumatology 1990 criteria for the classification of Takayasu arteritis.
Arthritis Rheum 1990, 33:1129–34.
17. Aydin SZ, Yilmaz N, Akar S, Aksu K, Kamali S, Yucel E, Karadag O,
Bicakcigil M, Ozer H, Kiraz S, Onen F, Inanc M, Keser G, Akkoc N,
Direskeneli H: Assessment of disease activity and progression in
Takayasu’s arteritis with Disease Extent Index-Takayasu.
Rheumatology (Oxford) 2010, 49:1889–93.
18. Misra R, Danda D, Rajappa SM, Ghosh A, Gupta R, Mahendranath KM,
Jeyaseelan L, Lawrence A, Bacon PA: Development and initial validation of
the Indian Takayasu Clinical Activity Score (ITAS2010).
Rheumatology (Oxford) 2013, 52:1795–801.
19. Hoffman GS, Ahmed AE: Surrogate markers of disease activity in patients
with Takayasu arteritis. A preliminary report from The International
Network for the Study of the Systemic Vasculitides (INSSYS). Int J Cardiol
1998, 66(66 Suppl 1):S191–S194. discussion S195.
20. Salvarani C, Cantini F, Boiardi L, Hunder GG: Laboratory investigations
useful in giant cell arteritis and Takayasu’s arteritis. Clin Exp Rheumatol
2003, 21:S23–8.
21. Ishihara T, Haraguchi G, Tezuka D, Kamiishi T, Inagaki H, Isobe M: Diagnosis
and assessment of Takayasu arteritis by multiple biomarkers. Circ J 2013,
77:477–83.
22. Tso E, Flamm SD, White RD, Schvartzman PR, Mascha E, Hoffman GS:
Takayasu arteritis: utility and limitations of magnetic resonance imaging
in diagnosis and treatment. Arthritis Rheum 2002, 46:1634–42.
23. Dagna L, Salvo F, Tiraboschi M, Bozzolo EP, Franchini S, Doglioni C, Manfredi
AA, Baldissera E, Sabbadini MG: Pentraxin-3 as a marker of disease activity
in Takayasu arteritis. Ann Intern Med 2011, 155:425–33.
24. Park MC, Lee SW, Park YB, Lee SK: Serum cytokine profiles and their
correlations with disease activity in Takayasu’s arteritis. Rheumatology
(Oxford) 2006, 45:545–8.
25. de Souza AW, de Lima CS, Oliveira AC, Machado LS, Pinheiro FA, Hix S,
D’Almeida V: Homocysteine levels in Takayasu arteritis – a risk factor for
arterial ischemic events. J Rheumatol 2013, 40:303–8.
26. Yilmaz H, Gerdan V, Kozaci D, Solmaz D, Akar S, Can G, Gulcu A, Goktay Y,
Sari I, Birlik M, Akkoc N, Onen F: Ghrelin and adipokines as circulating
markers of disease activity in patients with Takayasu arteritis. Arthritis Res
Ther 2012, 14:R272.
27. Yamada I, Nakagawa T, Himeno Y, Numano F, Shibuya H: Takayasu arteritis:
evaluation of the thoracic aorta with CT angiography. Radiology 1998,
209:103–9.
28. Mavrogeni S, Dimitroulas T, Chatziioannou SN, Kitas G: The role of
multimodality imaging in the evaluation of Takayasu arteritis.
Semin Arthritis Rheum 2013, 42:401–12.
29. Budtz-Lilly JW, Paaske W, Thrysoe SA, Andersen G: Takayasu’s arteritis and
the utility of magnetic resonance imaging. J Vasc Surg 2012, 56:832.
30. Schneeweis C, Schnackenburg B, Stuber M, Berger A, Schneider U, Yu J,
Gebker R, Weiss RG, Fleck E, Kelle S: Delayed contrast-enhanced MRI of the
coronary artery wall in takayasu arteritis. PLoS One 2012, 7:e50655.
31. Yamada I, Nakagawa T, Himeno Y, Kobayashi Y, Numano F, Shibuya H:
Takayasu arteritis: diagnosis with breath-hold contrast-enhanced
three-dimensional MR angiography. J Magn Reson Imaging 2000,
11:481–7.
32. Pipitone N, Versari A, Salvarani C: Role of imaging studies in the diagnosis
and follow-up of large-vessel vasculitis: an update. Rheumatology (Oxford)
2008, 47:403–8.
33. Kissin EY, Merkel PA: Diagnostic imaging in Takayasu arteritis. Curr Opin
Rheumatol 2004, 16:31–7.
34. Webb M, Chambers A, Adil AL-N, Mason JC, Maudlin L, Rahman L, Frank J:
The role of 18 F-FDG PET in characterising disease activity in Takayasu
arteritis. Eur J Nucl Med Mol Imaging 2004, 31:627–34.
35. Meller J, Grabbe E, Becker W, Vosshenrich R: Value of F-18 FDG hybrid
camera PET and MRI in early takayasu aortitis. Eur Radiol 2003, 13:400–5.
36. Wenger M, Calamia KT, Salvarani C, Moncayo R, Schirmer M: Do we need
18 F-FDG-positron emission tomography as a functional imaging
technique for diagnosing large vessel arteritis? Clin Exp Rheumatol 2003,
21:S1–2.
O’Connor et al. BMC Neurology 2014, 14:62 Page 9 of 9
http://www.biomedcentral.com/1471-2377/14/6237. Kusunose K, Yamada H, Tomita N, Nishio S, Niki T, Yamaguchi K, Koshiba K,
Yagi S, Taketani Y, Iwase T, Soeki T, Wakatsuki T, Akaike M, Sata M: Serial
imaging changes during treatment of Takayasu arteritis with pulmonary
artery stenosis. Int J Cardiol 2011, 148:e47–50.
38. Sager S, Yilmaz S, Ozhan M, Halac M, Ergul N, Ciftci H, Cermik TF: F-18 Fdg
PET/CT Findings of a Patient with Takayasu Arteritis Before and After
Therapy. Mol Imaging Radionucl Ther 2012, 21:32–4.
doi:10.1186/1471-2377-14-62
Cite this article as: O’Connor et al.: Role of inflammatory markers in
Takayasu arteritis disease monitoring. BMC Neurology 2014 14:62.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
